Investors are eagerly awaiting Photocures OSL:PHO Q2 2019 report to get a more indepth description of the recently announced Cevira partnership deal. Also key is the information about the current growth rate on Cysview sales in US. NOK 60-64 is a key level of expected resistance, as it is where the share price peaked in 2018, while a negative reaction could...
The biotech sector fell today news that Donald Trump intends to sign an executive order demanding that pharmaceutical companies give the US government "favored nation" prices. The news may not be as bad as it sounds, because Trump is apparently only launching a pilot program that will effect a small number of drugs. However, it's hard to predict the market's...
"Microsoft and Adaptive Biotechnologies announce partnership using AI to decode immune system; diagnose, treat disease" They also have a partnership with Genentech (January 2019) ADPT - Adaptive Biotechnology IPO: June 27th 2019 - open @$39 (above current price) Vision: We aim to improve people’s lives by translating the scale and precision of their...
There is a good RRR to enter XBI today. We seem to be in a bullish channel (showed in chart). IMMU - Which is 1.5% of the sector, is also a good option. (higher risk - higher reward).
Recent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company for updated Phase 1/2 Results for SB-525 . This is an investigational Hemophilia-A gene therapy that showed sustained increased Factor VIII Levels with no reported...
Eyepoint pharmaceuticals today was added to the Russell 2000 and 3000. The pharmaceutical company has alot to prove this quarter with regards to their loan with CRG, but a earnings beat would spark investor/ hedge fund investment which could give potential massive upside for EYPT and current investors. Why EYPT After EYPT diluted (one of EYPT's pain points) more...
Photocure OSL:PHO today released news of a outlicensing of the Cevira franchise for commercialization, giving the stock a boost, possibly regaining foothold above the SMA50 and SMA200. Press release photocure.com
Nice volume on Friday. Looking at calls on a break of Friday's high.
Back test of recent breakout after three months of consolidation.
Nice volume on Friday, recent breakout after 2 months of consolidation, BBs expanding.
Nice volume bars this past week, appears to be consolidating for a move up. Looking at August calls in this name.
Last week, ENZO BIOCHEM INC - NYSE:ENZ broke to higher ground and in the process, recaptured its 200 DMA out of a rounding bottom and now finds itself digesting/consolidating the move within a Flag pattern on lower volume as is evidenced in the Daily chart above. In addition, ENZ is now trading above all of its important moving averages 20/50/200 DMA's and...
Congratulations MLNT holders. Target of $7 is roughly reached. Fractal tells us to take profit. But people will still chase the expansion breakout. It's a gamble as always.
In my previous post on #CRISPR I talked about the Green upward sloping trendline & how every time CRSPR has traded on or below it since May 2017 we've seen parabolic action. I don't want to say I told you so, but we've seen some parabolic action. To my surprise, the parabolic movement came the news of Vertex upfront payment of $175 million upfront payment....
For the past year, FLEX PHARMA INC - NASDAQ:FLKS has found itself in base mode with the exception of a handful of sharp violent upside moves accompanied with large volume as is evidenced in the Daily chart above. In addition, we can observe that FLKS presently finds itself trading above all of its important moving averages 20/50/200 DMA's, which is...